RZLT News and Press, Rezolute Inc. From 12/15/22

REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that the Compan...

Rezolute press release ( NASDAQ: RZLT ): Q1 GAAP EPS of -$0.19. Cash and cash equivalents totaled $154.3 million as of September 30, 2022. For further details see: Rezolute GAAP EPS of -$0.19

Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potent...

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that ...

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it wi...

Rezolute press release ( NASDAQ: RZLT ): Q4 GAAP EPS of -$0.37. Cash and cash equivalents totaled $150.4 million as of June 30, 2022. For further details see: Rezolute GAAP EPS of -$0.37

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022 Phase 2 proof-of-concept study of RZ402 expected to be initiated later this ...

Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapie...

Rezolute (NASDAQ:RZLT) on Friday filed for resale of 10.9M shares by selling stockholders, issuable on the exercise of 10.9M class B warrants. The warrants have an exercise price of $0.001/share. RZLT will receive up to ~$10K from the exercise of warrants. Net proceeds from the exercise ...

Cantor Fitzgerald has initiated Rezolute (NASDAQ:RZLT) at overweight citing the company's lead candidate RZ358 for congenital hyperinsulinism as it could be a more than $500M revenue generator by 2030. The firm has a $9 price target (197% upside based on Tuesday's close). Analyst Pete St...